LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN. In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients. She listens to them; she learns from them; and then she searches for answers to their questions and her own. It was the process of learning and listening that first made her curious about cannabis. How could a drug so vilified treat such a wide array of disorders from Parkinson's to chronic pain?
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8308956-gb-sciences-meredith-patterson-weed-nurse-science-of-cbd/
CBD & Pain Relief Via a Receptor Called Vanilloid
One such CBD receptor is "TRPV1" which is the technical abbreviation for "transient receptor potential cation channel subfamily V." Now that's quite a mouthful so I prefer another known name for the same receptor – Vanilloid –so dubbed because it has similar effects to the vanilla bean. Vanilla contains eugenol, an essential oil that has antiseptic and analgesic properties. When CBD binds with TPRV1 (aka the Vanilloid receptor) a process is activated to mediate pain perception, inflammation and body temperature.
So, the pain relief that CBD is known for is not because of the direct ingestion of the cannabinoid but in the way that it interacts with particular receptors. As you might expect, researchers and CBD consumers are making more noise about both clinical and anecdotal evidence of pain relief. A 2008 review examined two decades' worth of preclinical studies and animal trials before concluding that CBD can be a successful tool for pain management without many adverse side effects. Another 2016 study by the University of Kentucky examined CBD's effects on arthritic rats and found that the compound reduced inflammation and overall pain. Just now as I screened for "pain" and "CBD" in my go-to website for current research, clinicaltrials.gov, 47 studies popped up.
Things are happening. Stay tuned!
Meredith now writes a series of popular sciences blogs in which she explains all the benefits, dispels the misconceptions and helps put minds at ease about a drug that's been vilified for so long. What follows is her second in a series of blogs which focus on CBD.
GB Sciences' Chairman and CEO John Poss comments, "Meredith is an important part of the GB team. Her experience and intellectual curiosity bring to the public a better understanding of the medical foundations of cannabis."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Meredith Patterson, RN, BSN, CRRN
Meredith is a registered nurse with over 25 years of neuroscience nursing experience
in a variety of settings including intensive care, head injury acute care rehabilitation,
sub-acute and dementia care. She has authored numerous presentations and continuing
education classes for nursing professionals and is a frequent presenter for community and
professional audiences including the University of Texas Health Science Center, Scott
and White Hospital, Texas State University and the annual Alzheimer's Symposium in
Meredith is a graduate of the University of Texas Health Science Center in San Antonio
and she is certified in rehabilitation nursing. She is past president of the Association of
Rehabilitation Nurses of San Antonio and has served as a reviewer for the journal of the
Association of Neuroscience Nurses.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Tom Arcuragi, EVP, firstname.lastname@example.org
SOURCE GB Sciences, Inc.